June 5, 2017 Bio/Pharma/CRO PR/Corporate

Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer

Basel, 05 June 2017 Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa... Read more

June 5, 2017 Bio/Pharma/CRO PR/Corporate

Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer

Basel, 05 June 2017 Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa... Read more

June 5, 2017 PR/Corporate

APHINITY study shows Roche’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer

Basel, 05 June 2017 APHINITY study shows Roche’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer Phase III study confirms benefit of the Perjeta-based regimen over the current standard of care The study was positive in the overall population, with greatest risk reduction in... Read more

June 3, 2017 PR/Corporate Product Launch

Roche presents new data for TECENTRIQ® (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017

Basel, 03 June 2017 Roche presents new data for TECENTRIQ® (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017 Data evaluated TECENTRIQ in novel combinations across a broad range of tumours including lung, kidney and melanoma Promising Phase II combination data with TECENTRIQ plus Avastin (bevacizumab) in advanced kidney cancer First... Read more

May 24, 2017 Licensing, IP, and Legal Product Launch

New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF)

Basel, 24 May 2017 New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) In new post hoc analyses of phase III data, Esbriet reduced the risk of death in patients with more advanced lung function impairment and the risk of respiratory-related hospitalisations as a first... Read more

May 24, 2017 Licensing, IP, and Legal Product Launch

New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF)

Basel, 24 May 2017 New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) In new post hoc analyses of phase III data, Esbriet reduced the risk of death in patients with more advanced lung function impairment and the risk of respiratory-related hospitalisations as a first... Read more

May 23, 2017 PR/Corporate

Reminder: Invitation to Roche Analyst Event at ASCO 2017

Basel, 23 May 2017 Reminder: Invitation to Roche Analyst Event at ASCO 2017 Monday, 5 June 2017, 5:15pm CDT We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (2 –... Read more

May 23, 2017 Acad, Gov/Utilities Clinical Research/Diagn.

FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis

Basel, 23 May 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis Actemra/RoActemra is the first FDA-approved treatment for adults with giant cell arteritis (GCA) FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra/RoActemra in GCA Sixth FDA approval for Actemra/RoActemra since its US launch in 2010 Roche (SIX: RO, ROG; OTCQX:... Read more

May 23, 2017 Acad, Gov/Utilities Microscopy

FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis

Basel, 23 May 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis Actemra/RoActemra is the first FDA-approved treatment for adults with giant cell arteritis (GCA) FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra/RoActemra in GCA Sixth FDA approval for Actemra/RoActemra since its US launch in 2010 Roche (SIX: RO, ROG; OTCQX:... Read more

May 18, 2017 PR/Corporate

Invitation: Roche Analyst Event at ISTH 2017

Basel, 18 May 2017 Invitation: Roche Analyst Event at ISTH 2017 Monday, 10 July 2017, 6:30pm CEST We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017. During the briefing, Roche will discuss new data for... Read more